Protective threshold of a potent neutralizing Zika virus monoclonal antibody in rhesus macaques
Journal of Virology · 2024
DOI: 10.1128/jvi.01429-24 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Virology, 2024. Verfasst von Joseph P Nkolola und 12 weiteren Autor:innen. Beteiligte Einrichtung: Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA. Hauptthemen laut MEDLINE: Macaca mulatta, Zika Virus, Zika Virus Infection, Antibodies, Neutralizing. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS, DOD | ARPA | Defense Sciences Office, DARPA (DSO).
Abstract (Originalsprache)
Zika virus (ZIKV) is a mosquito-borne flavivirus that caused a global pandemic in 2016–2017 with continued ongoing transmission at low levels in several countries. In the absence of an approved ZIKV vaccine, neutralizing monoclonal antibodies (mAbs) provide an option for the prevention and treatment of ZIKV infection. Previous studies identified a potent neutralizing human mAb ZIKV-117 that reduced fetal infection and death in mice following ZIKV challenge. In this study, we report exquisite potency of ZIKV-117-LALA-YTE, which has been engineered to reduce Fc receptor binding and to extend half-life, in a titration study in rhesus macaques to protect against ZIKV challenge. We show complete protection at a dose of 0.016 mg/kg ZIKV-117-LALA-YTE, which resulted in median serum concentrations of 0.13 µg/mL. The high potency of this mAb supports its potential clinical development as a novel biotherapeutic intervention for ZIKV. IMPORTANCE In this study, we report the potency of the Zika virus (ZIKV)-specific neutralizing antibody ZIKV-117-LALA-YTE against ZIKV challenge in a titration study rhesus macaques. This high potency supports the further development of this monoclonal antibody for ZIKV.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA.
- Bioqual, Rockville, Maryland, USA.
- Vanderbilt Vaccine Center, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
- Department of Pediatrics, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
- Department of Pathology, Microbiology, and Immunology, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
ORCID-Profile: Joseph P Nkolola, James E Crowe, Dan H Barouch
Förderung
- NIAID NIH HHS
- DOD | ARPA | Defense Sciences Office, DARPA (DSO)
Zitieren
APA
Nkolola, J. P., Hope, D., Guan, R., Colarusso, A., Aid, M., Weiss, D., Misamore, J., Andersen, H., Lewis, M. G., Williamson, L., Carnahan, R. H., Crowe, J. E., & Barouch, D. H. (2024). Protective threshold of a potent neutralizing Zika virus monoclonal antibody in rhesus macaques. Journal of Virology. https://doi.org/10.1128/jvi.01429-24
Vancouver
Nkolola JP, Hope D, Guan R, Colarusso A, Aid M, Weiss D, et al. Protective threshold of a potent neutralizing Zika virus monoclonal antibody in rhesus macaques. Journal of Virology. 2024. doi:10.1128/jvi.01429-24
BibTeX
@article{Nkolola2024,
author = {Nkolola, Joseph P and Hope, David and Guan, Ruoran and Colarusso, Alessandro and Aid, Malika and Weiss, Deborah and Misamore, John and Andersen, Hanne and Lewis, Mark G and Williamson, Lauren and Carnahan, Robert H and Crowe, James E and Barouch, Dan H},
title = {Protective threshold of a potent neutralizing Zika virus monoclonal antibody in rhesus macaques},
journal = {Journal of Virology},
year = {2024},
doi = {10.1128/jvi.01429-24}
}
EUVIMED